Literature DB >> 2452032

Study of histamine release induced by acute administration of antitumor agents in dogs.

A Eschalier1, J Lavarenne, C Burtin, M Renoux, E Chapuy, M Rodriguez.   

Abstract

The effects of eight antitumoral drugs known to cause anaphylactoid side effects in clinical use were studied in dogs. Blood pressure, heart rate, and blood and plasma histamine levels were monitored. L-asparaginase, methotrexate, 5-fluorouracil, bleomycin, and cisplatin had no effect on these parameters. Doxorubicin, Vehem (teniposide), and Vepeside (etoposide) induced hypotension, tachycardia, and a rise in histamine levels. In the cases of Vehem and Vepeside, the excipient (respectively, cremophor EL and tween 80) induced the same effects. These agents, like elliptinium, which had been previously studied, induce nonspecific histamine release--unlike the other drugs studied. The mechanism of clinically observed anaphylactoid side effects is discussed in the light of these findings.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452032     DOI: 10.1007/bf00262779

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

1.  Anaphylactic reaction to high-dose methotrexate.

Authors:  I Gluck-Kuyt; L E Irwin
Journal:  Cancer Treat Rep       Date:  1979-05

2.  Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.

Authors:  G Mathé; L Schwarzenberg; P Pouillart; R Oldham; R Weiner; C Jasmin; C Rosenfeld; M Hayat; J L Misset; M Musset; M Schneider; J L Amiel; F De Vassal
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  Pyrogenic properties of bleomycin (NSC-125066).

Authors:  C A Dinarello; S B Ward; S M Wolff
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

4.  Hypersensitivity reaction to cancer chemotherapy.

Authors:  R B Weiss
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

5.  Protein-methotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy.

Authors:  M da Costa; W Isacoff; S P Rothenberg; M P Iqbal
Journal:  Cancer       Date:  1980-08-01       Impact factor: 6.860

6.  Systemic allergic reaction to adriamycin.

Authors:  D J Arnold; C T Stafford
Journal:  Cancer Treat Rep       Date:  1979-01

7.  [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].

Authors:  J Rouesse; T Tursz; T Le Chevalier; D Huertas; J L Amiel; G Brule; B Callet; J P Droz; P M Voisin; H Sancho-Garnier; J B Le Pecq; C Paoletti
Journal:  Nouv Presse Med       Date:  1981-05-30

8.  Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.

Authors:  F A Hayes; M Abromowitch; A A Green
Journal:  Cancer Treat Rep       Date:  1985-04

9.  Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release.

Authors:  M R Bristow; W S Sageman; R H Scott; M E Billingham; R E Bowden; R S Kernoff; G H Snidow; J R Daniels
Journal:  J Cardiovasc Pharmacol       Date:  1980 Sep-Oct       Impact factor: 3.105

10.  Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.

Authors:  E H Herman; R S Young
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec
View more
  9 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

3.  Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors:  S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.

Authors:  Tom van den Ende; Stef P Menting; Carmen A Ambarus; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Oncologist       Date:  2019-03-22

5.  Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.

Authors:  Mary Kay Blake; Brittany J Carr; Glenna E Mauldin
Journal:  Can Vet J       Date:  2016-02       Impact factor: 1.008

Review 6.  Presentation and management of docetaxel-related adverse effects in patients with breast cancer.

Authors:  Maria Y Ho; John R Mackey
Journal:  Cancer Manag Res       Date:  2014-05-27       Impact factor: 3.989

7.  Justification for species selection for pharmaceutical toxicity studies.

Authors:  Helen Prior; Richard Haworth; Briony Labram; Ruth Roberts; Alison Wolfreys; Fiona Sewell
Journal:  Toxicol Res (Camb)       Date:  2020-11-24       Impact factor: 3.524

8.  Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.

Authors:  J Siderov; P Prasad; R De Boer; J Desai
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

9.  Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report.

Authors:  David Starks; Deborah Prinz; Amy Armstrong; Lindsay Means; Steven Waggoner; Robert Debernardo
Journal:  Case Rep Obstet Gynecol       Date:  2011-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.